UnitedHealth Group (UNH) Q1 2026 Earnings — Core Brief Edition

Headline: UnitedHealth opened 2026 with a cleaner-than-expected quarter as pricing discipline, favorable reserve development, and sharper Optum Health execution offset still-elevated medical trends, while management nudged full-year EPS above $18.25 and leaned harder into an AI-led operating reset.

Key Metrics

Total revenue: $111.7B (+2% YoY).
Adjusted EPS: $7.23, ahead of management’s expectations.
Medical care ratio: 83.9% vs. 84.8% in Q1 2025.
Operating cost ratio: 13.8%.
Operating cash flow: $8.9B, or 1.4x net income.
Total domestic members: 49.1M, down from 49.8M at year-end 2025.
Optum Health adjusted earnings: $1.3B.
Optum Health patients served: 20M+, including 4M+ in fully value-based arrangements.
AI investment plan for 2026: nearly $1.5B.
Incentive compensation accrual: approximately $900M vs. $35M in Q1 2025.

🧩 Segment & Strategy Highlights

UnitedHealthcare: Medicare and retirement performed with disciplined pricing in an elevated but stable trend environment. Commercial results tracked pricing and trend assumptions, while management stayed focused on margin recovery over membership growth, especially in Medicare and commercial. Medicaid remained pressured by inadequate state rates; management still expects membership attrition and negative margins in 2026, with modest improvement starting in 2027.
Medicare Advantage: Trends stayed elevated but consistent with pricing assumptions. Management said 2026 pricing was built around roughly 10% pricing against 7–8% MA trend, with early-quarter experience showing only modest favorability in government programs and no inflection yet in utilization. Medicare membership is now expected to contract around 1.3M in 2026.
ACA / Commercial: ACA membership is still expected to decline by about one-third in 2026. UnitedHealth continues to focus ACA exposure on bronze and gold products and said Q1 reflects its pledge to refund any 2026 ACA profits. Self-funded commercial offerings remained solid.
Optum Health: The quarter benefited from favorable prior-period development, better contracts, cost control, and more disciplined value-based execution. Management reiterated a path toward 6%–8% long-term sustainable margins. In the West region, earlier clinical intervention helped drive an approximately 35% reduction in skilled nursing admissions in the first month versus last year.
OptumRx: Onboarded 800+ new clients, cut contact-center volume 25%, and kept member satisfaction above 95%. Scripts were down slightly YoY on membership mix/attrition, while specialty drugs now represent 50%+ of drug spend.
Optum Insight: Management is transitioning legacy products toward AI-first offerings. Optum Real can reduce manual contact costs by 76%, and Optum Financial agreed to acquire Allegis Technologies, with the deal expected to be accretive in 2027.

🤖 Product, Tech, AI

UnitedHealth remains on track to invest nearly $1.5B in AI in 2026, with roughly one-third aimed at software/products/platforms and two-thirds at enterprise processes and functions. Management expects a conservative 2:1 return over the next few years, with many projects paying back in 12–18 months.
UHC launched Avery, a generative AI chatbot, and expects to expand it to 20M+ members by year-end.
Digital prior auth products are gaining traction: the new Optum Insight solution already has payer/provider clients live, roughly 50 more clients in the pipeline, and early submissions are showing 96% first-pass approval rates.
Optum Real has processed 0.5B transactions year-to-date and is expected to exceed 2.5B by year-end. OptumAI has already signed its first consulting contracts, including with LabCorp.

🏥 Care Delivery & Utilization

Nearly 95% of medical prior authorization requests are now submitted electronically; about 50% are processed in real time, and 90%+ are approved within one business day on average. UnitedHealth aims to reduce the total number of medical prior authorizations by 30%+ by year-end.
UHC saw 73M digital visits in Q1, up 42% over the last two years. More than 80% of consumer contacts now come through digital channels, while provider transaction volumes rose 75% YoY and about 75% of in-network providers are using portal or API tools.
In Optum Health’s fee-for-service operations, new standards are in place across nearly 70% of settings and should reach nearly 80% by end-Q2, already driving a 12% YoY increase in patient-facing hours.

💰 Balance Sheet & Capital

Operating cash flow was $8.9B in Q1, helping reduce debt-to-capital to 42.9%, with management still targeting 40.0% by year-end.
UnitedHealth started buybacks earlier than expected and plans to deploy at least $2.0B by the end of Q2. Management said repurchases remain a priority given what it sees as a deep intrinsic-value discount in the stock.
The company booked a $525M gain on the sale of its UK business and directed $400M of the proceeds to the United Health Foundation.

🔭 Guidance / Outlook

FY2026 adjusted EPS outlook: updated to greater than $18.25. Management described this as a refreshed view after Q1 strength, while emphasizing it is still early in the year.
Earnings cadence is unchanged: about two-thirds of full-year earnings are still expected in 1H26 and the remaining one-third in 2H26.
UHC earnings are expected to be 75%+ weighted to the first half; Optum Health also remains heavily first-half weighted, while Optum Insight and OptumRx should each generate about 60% of earnings in the second half.
For Medicare Advantage, management said it feels good about achieving the previously previewed 50 bps year-over-year margin improvement in 2026 and is targeting the upper half of the 2%–4% long-term range in 2027.

Bottom Line

UnitedHealth’s Q1 was less about top-line acceleration and more about quality of execution: better pricing alignment, reserve support, steadier medical management, and a clearly improved Optum Health operating rhythm.

The bigger strategic message is that management is trying to rebuild margin durability while modernizing the platform around AI, digital workflows, and value-based care. Elevated utilization is still the main watch-item, but the company enters the rest of 2026 with stronger operational footing, an improved capital return posture, and a more constructive earnings setup than feared.